Rutgers Cancer Institute: Survival Benefit Lacking in Older Men Treated with Hormone Therapy for Early-Stage Prostate Cancer
New Brunswick, NJ, July 15, 2014 — Research from investigators at Rutgers Cancer Institute of New Jersey shows a popular prostate cancer treatment that disables male hormones known to promote growth of prostate cancer lacks survival benefit for older men with localized disease.
The study, “Fifteen-Year Survival Outcomes Following Primary Androgen Deprivation Therapy for Localized Prostate Cancer,” focuses on this specific treatment (also known as ADT) which for the past 15 years has become a popular alternative to surgery, radiation or conservative management when used as the only therapy.
Trenton, NJ, July 14, 2014 — New Jersey celebrates its 350th anniversary this year.
As part of the festivities and in cooperation with the State and NJBIZ, the New Jersey Chamber of Commerce is conducting a survey to determine the greatest innovations to come out of the Garden State throughout its long and rich history of innovation.
The survey’s results in eight categories — Healthcare, Medicine, Transportation, Energy, Entertainment/Communications, Food, Day-to-Day Living and Innovation Breakthroughs — will be announced at the Celebration Innovation Gala on October 27 at The Palace in Somerset.
To vote, click here.
New Brunswick, NJ, July 10, 2014 — RUCDR Infinite Biologics, a unit of Rutgers’ Human Genetics Institute of New Jersey, has taken a major step toward expanding its focus from conducting and supporting genomic research, where it’s become a recognized global leader, to the rapidly growing field of clinical genomics.
RUCDR, which is the world’s largest university-based biorepository, recently earned its initial certification from the federal Clinical Laboratory Improvement Amendments program. CLIA, as it’s commonly known in health care, is run by the Centers for Medicare and Medicaid Services (CMS) of the U.S. Department of Health and Human Services. Read the rest of this entry »
New Brunswick, NJ, July 8, 2014 — Robert S. DiPaola, MD, director of Rutgers Cancer Institute of New Jersey has been selected to receive the Melvyn H. Motolinsky Research Foundation Distinguished Service Award in recognition of his accomplishments and leadership in the field of oncology.
Dr. DiPaola who has international expertise as a prostate cancer physician and researcher, was viewed as a “luminary” in being chosen for this year’s honor, which is reserved for those who make a difference in the lives of many through leadership in healthcare, public health, public service or science. Read the rest of this entry »